Cystic Fibrosis and the Use of Pharmacogenomics to Determine Surrogate Endpoints for Drug Discovery

Author： Eidelman O.   Zhang J.   Srivastava M.   Pollard H.B.  

Publisher： Adis International

ISSN： 1175-2203

Source： American Journal of PharmacoGenomics, Vol.1, Iss.3, 2001-01, pp. : 223-238

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Towards the pharmacogenomics of cystic fibrosis

By Sangiuolo Federica   D’Apice Maria Rosaria   Bruscia Emanuela   Lucidi Vincenzina   Novelli Giuseppe  

Pharmacogenomics, Vol. 3, Iss. 1, 2002-01 ,pp. : 75-87

Future Medicine

Access to resources Recommend Favorite

Toward the pharmacogenomics of cystic fibrosis – an update

By Sangiuolo Federica   D’Apice Maria Rosaria   Gambardella Stefano   Di Daniele Nicola   Novelli Giuseppe  

Pharmacogenomics, Vol. 5, Iss. 7, 2004-10 ,pp. : 861-878

Future Medicine

Access to resources Recommend Favorite

Editorial (Thematic Issue: Cystic Fibrosis: Pathophysiology and Drug Discovery)

By  

Clinical Immunology, Endocrine & Metabolic Drugs, Vol. 3, Iss. 2, 2017-08 ,pp. : 80-81

Bentham Science Publishers

Access to resources Recommend Favorite

Drug Disposition in Cystic Fibrosis

By Rey E.   Tréluyer J-M.   Pons G.  

Clinical Pharmacokinetics, Vol. 35, Iss. 4, 1998-10 ,pp. : 313-329

Adis International

Access to resources Recommend Favorite

Pharmacogenomics: Integration into Drug Discovery and Development

By  

Current Topics in Medicinal Chemistry, Vol. 5, Iss. 11, 2005-09 ,pp. : 1039-1046

Bentham Science Publishers

Access to resources Recommend Favorite